<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379845</url>
  </required_header>
  <id_info>
    <org_study_id>NBTXR3-301</org_study_id>
    <nct_id>NCT02379845</nct_id>
  </id_info>
  <brief_title>NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall</brief_title>
  <official_title>MULTICENTER RANDOMIZED, OPEN-LABEL PHASE II/III STUDY, TO COMPARE EFFICACY OF NBTXR3 IMPLANTED AS INTRATUMOR INJECTION AND ACTIVATED BY RADIOTHERAPY, VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA (EXTREMITY AND TRUNK WALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanobiotix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaEngine</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanobiotix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy given before surgery of soft tissue sarcoma decreases the size
      of the tumor mass and the presence of malignant cells in its peripheral region. NBTXR3 and
      radiation therapy may kill more cancer cells and increase the tumor shrinkage rendering
      surgery more feasible or easier and achieve better local control of the tumor.

      PURPOSE: This phase II/III is a prospective randomized, multi-center, open-label and active
      controlled two arms study in patients with locally advanced soft tissue sarcoma (STS) of the
      extremity and trunk wall. Patients will be randomized to receive either NBTXR3 as intratumor
      injection, activated by external beam radiation therapy or external beam radiation therapy
      alone, as preoperative treatment. Once the radiotherapy treatment is completed, tumor surgery
      will be performed in all patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who will be allocated in arm A, will receive a single intratumor injection of NBTXR3
      and will receive external beam radiotherapy starting 24hrs after the injection up to
      completion of 5 weeks, 5 days a week of treatment (50Gy, 2Gy/fraction). Then, all patients
      will undergo surgical resection of the tumor 5 weeks later and will be followed for wound
      Healing and toxicity assessment. A visit of end of treatment will take place approximately
      3-4 weeks after surgery. Patients will be followed for evaluation of their disease status and
      adverse event until the end of study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response Rate (pCRR)</measure>
    <time_frame>36 months</time_frame>
    <description>To compare antitumor activity in terms of Pathological complete response rate (pCRR) of intratumor injection of NBTXR3 activated by external beam radiation therapy (EBRT), versus EBRT alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of early and late TEAE, post-TEAE, SAE and laboratory abnormalities (NCI CTCAE V4.0)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) by Imaging (MRI) according to RECIST 1.1</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor volume changes (theoretical tumor volume estimated as: Lenght x Width x Depth</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection Margins (R0, R1, R2)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb amputation rate</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Local and distant recurrence rate</measure>
    <time_frame>12 months and 24 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Adult Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NBTXR3 + Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NBTXR3</intervention_name>
    <description>One intratumor implantation by injection</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>PEP503</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>5 weeks/50 Gy (5 x 2 Gy by week)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 years and older

          -  Locally Advanced Soft Tissue Sarcoma of the Extremity and Trunk Wall

          -  All grades

          -  Candidate to radiotherapy + surgery (ESMO guideline 2014) i.e. tumor must not have
             involvement of bone and / or vessel and or nerve :

               -  Primary tumor or,

               -  Relapsed tumor, localized out of previously irradiated area

          -  WHO performance score 0 to 2

          -  Adequate function of bone marrow

          -  Adequate renal function

          -  Adequate hepatic function

          -  Adequate pulmonary function

          -  All female patients of childbearing potential must have a negative serum/urinary
             pregnancy test

        Exclusion Criteria:

          -  Absence of written Informed Consent duly signed and dated

          -  Patients with the following histological type: embryonal or alveolar rhabdomyosarcoma,
             Ewing's sarcoma, osteosarcoma or chondrosarcoma, Kaposi's sarcoma, primitive
             neuroectodermal tumor, angiosarcoma, aggressive fibromatosis or dermatofibrosarcoma
             protuberans

          -  Soft Tissue Sarcoma of the Trunk Wall localized in the abdominal region i.e. the
             region defined cranially by the xiphoid process of the sternum and the costal margins,
             and caudally by the line joining the anterior superior iliac spines, both limited by
             the perpendicular lines crossing both nipples

          -  Patient with a calculated tumor baseline volume &gt; 3000 mL

          -  Metastatic disease (CT-scan / MRI verification) with life expextancy shorter than 6
             months

          -  Previous radiation therapy in relapse site of soft tissue sarcoma (no radiation
             re-chanllenge is permitted)

          -  Concurrent treatment with any other anticancer therapy, including chemotherapy,
             immunotherapy, targeted therapy, gene therapy, or patients planning to receive these
             treatments during the study

          -  Absence of histologically or cytologically proven cancer at the first diagnosis

          -  Previous neoadjuvant chemotherapy treatment given as an upfront of the current
             treatment line

          -  Hemolytic anemia

          -  Autoimmune disease

          -  Complete initial work up earlier than 4 weeks prior to patient registration

          -  Patients unable to comply with scheduled visites, treatment plans, laboratory tests,
             and other study procedures

          -  Patients participating in another clinical investigation at the time of signature of
             the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Capital Region Cancer Service, Canberra Hospital</name>
      <address>
        <city>Canberra</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <state>Saint Herblain</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre Le Cancer Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princes of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre, Hungarian Defence Forces</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Pècs</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology Veneto IOV</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital Cebu</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Santo Thomas</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical City</name>
      <address>
        <city>Pasig City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center Institute</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Bucuresti</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalului Universitar de Urgenta Militar Central</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amethyst-Cluj</name>
      <address>
        <city>Floresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital 'Dr Gavril Curteanu'</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital, Targu Mures</name>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Emergency Hospital</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iatros International</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Oncology Centre</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gvi Outeniqua Oncology Unit</name>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilgers Oncology Centre</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START MADRID, Hospital Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START MADRID, Hospital Universitario Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>March 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>June 1, 2018</last_update_submitted>
  <last_update_submitted_qc>June 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

